The present invention relates to an intercellular adhesion molecules-3 (ICAM-3) or a functional derivative of said molecule which, substantially free of natural contaminants, said derivative comprising a fragment of ICAM-3 selected from the group consisting of following sequences of aminoacids : the ID sequence, numbers 2,4 and 6, the functional derivative of the adhesion molecule-3 contains a sequence of aminoacids selected from the group consisting of D1, D1-2, D1-3, D1-4 and D1-5 of ICAM-3 the recombinant DNA molecule capable of encoding ICAM-3 or a functional derivative of it includes at least one fragment selected from the group consisting of the following sequences of nucleotides; the ID sequence, numbers 1, 3 and 5 This DNA recombinant molecule is capable of expressing ICAM-3 or a functional derivatives thereof in a cell The characteristics of monoclonal antibody or the antibody fragment capable of binding to a molecule selected from the group consisting of ICAM-3 or a functional derivatives thereof lies in that the binding of this antibody to the molecule affects the capability of binding to a receptor molecule The receptor is selected from LFA-1, MAC-1 and p 15095 The hybridoma cell is capable of producing the said monoclonal antibody The pharmaceutical compositions include an agent selected from a group which consists of an antibody capable binding to ICAM-3 ; a fragment of said antibody, said fragment being capable of binding to ICAM-3; ICAM-3; a functional derivative of ICAM-3 and a non-imunoglobulinic antagonist of ICAM-3, other than ICAM-1, ICAM-2 or a member of the CD-18 family The pharmaceutical composition also comprises an immunosupressive agent
展开▼
